1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Rheumatoid Arthritis: KOL Insight [2018]

Rheumatoid Arthritis: KOL Insight [2018]

  • March 2018
  • ID: 5385563
  • Format: PDF
  • By Firstword Pharma

Summary

Table of Contents

How is Olumiant impacting the RA treatment landscape?

After several years on the US market, the availability of Pfizer’s Xeljanz in the EU is generally welcomed by KOLs; however, Eli Lilly/Incyte’s Olumiant (baricitinib) has managed to get first-to-market advantage in Europe. KOL’s weigh in on how Olumiant is faring in the EU, how its availability is impacting Xeljanz, as well as its chances to garner FDA approval. KOLs also examine Sanofi/Regeneron’s Kevzara (sarilumab) and how this new IL-6 inhibitor is faring. Furthermore, the experts discuss how AbbVie’s upadacitinib (ABT 494) and Galapagos/Gilead Sciences’ filgotinib shape up in an ever competitive JAK inhibitor market, as well as how Can-Fite’s piclidenoson (CF 101) could disrupt the treatment paradigm. Experts also give their views on biosimilar anti-TNF uptake and the challenges branded anti-TNFs may face. Twelve US and European KOLs offer their candid insights on these issues and more.

Take a tour of the report now
• The table of contents >
• The key business questions answered >
• The key KOL quotes >
• See the therapies covered >
• Find out who the 6 EU & 6 US KOLs are >
• Review an extract from the report - 1 drug profile >

Top takeaways
• Biosimilar anti-TNFs are now part of the treatment paradigm. How do KOLs use these products and are there differences between US and European prescribing?
• Cimzia and Simponi have no biosimilar competition. But what impact have other biosimilar anti-TNFs had on these two agents?
• How well is Olumiant faring in Europe? Can Pfizer’s Xeljanz fend off competition from this product and will Olumiant be approved in the US?
• Actemra/RoActemra is a standard second-line therapy. But is usage expected to decline in the future, and what could Roche do to maintain market share?
• What impact has Kevzara had on the RA market? KOLs weigh in on Kevzara’s advantages/disadvantages and provide insights on current usage.
• Upadacitinib and filgotinib may provide specific advantages. Are these products perceived as real competitors to Xeljanz and Olumiant?
• KOLs discuss future developments that may play a part in shaping the future treatment of RA. What are KOLs’ thoughts on future general trends and how will these impact RA treatment in the future?

Quotes

“Upadacitinib is showing signs of JAK2 inhibition as well. Whether this is a good thing or a bad thing, nobody knows.”European Key Opinion Leader

“Rituximab has always been kind of niche drug, especially in RA, it’s more the end of the line. In RA it’s always going to be third or fourth line biologic.” US Key Opinion Leader

Sample of therapies covered

Marketed Therapies
• Anti-TNFs
• Humira (adalimumab; AbbVie)
• Enbrel (etanercept; Amgen/Pfizer)
• Remicade (infliximab; Janssen Biotech/Merck & Co.)
• Cimzia (certolizumab pegol; UCB)
• Simponi (golimumab; Janssen Biotech/Merck & Co.)
• Biosimilar anti-TNFs: companies involved in biosimilar anti-TNFs: Sandoz; Amgen; Samsung Bioepis/Biogen; Celltrion/Pfizer; Boehringer Ingelheim
• Actemra/RoActemra (tocilizumab; Roche)
• Kevzara (sarilumab; Sanofi/Regeneron)
• Orencia (abatacept; Bristol-Myers Squibb)
• Rituxan/MabThera (rituximab; Roche/Biogen)
• Xeljanz (tofacitinib; Pfizer)
• Olumiant (baricitinib; Incyte/Eli Lilly)

Pipeline Therapies
• olokizumab (R-Pharm/UCB)
• upadacitinib (ABT 494; AbbVie)
• filgotinib (GLPG 0634; Galapagos/Gilead Sciences)
• piclidenoson (CF 101; Can-Fite)

Earlier stage
• mavrilimumab (CAM 3001; AstraZeneca)
• Bruton kinase inhibitors (e.g. Merck Serono’s evobrutinib)

KOLs interviewed

KOLs from North America
• Prof Michael E Weinblatt, MD, is Professor of Medicine at Harvard Medical School. Dr. Weinblatt serves as Co-director of Clinical Rheumatology at the Brigham and Women’s Hospital.
• Dr Petros Efthimiou, MD, is Associate Chief of Rheumatology at New York Methodist Hospital, and an Associate Professor of Medicine and Rheumatology at Weill Cornell Medical College.
• Prof Fleischmann, MD, is Clinical Professor of Medicine at the University of Texas Southwestern Medical Center at Dallas, and co-Medical Director of the Metroplex Clinical Research Center in Dallas, TX.
• Prof Jeffrey R Curtis, MD, is Professor of Medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham.
• Dr Rohit Aggarwal MD, isAssociate Professor of Medicine and Medical Director, Arthritis and Autoimmunity Center, Division of Rheumatology, Department of Medicine at the University of Pittsburgh, Pittsburgh, PA, USA.
• Dr Roberto Caricchio, MD, isInterim Section Chief, Rheumatology; Associate Professor, Medicine; Associate Professor, Microbiology and Immunology; and Director at Temple Lupus Clinic, Temple University, Philadelphia, PA, USA.

KOLs from Europe
• Prof Paul Emery, is the Arthritis Research UK Professor of Rheumatology and Director of the Leeds Institute of Rheumatic and Musculoskeletal Medicine. He is also the Director of the Leeds Musculoskeletal Biomedical Research Unit at Leeds Teaching Hospitals Trust, UK.
• Prof Tore K Kvien, is Professor of Rheumatology at the University of Oslo and Head of the Department of Rheumatology at Diakonhjemmet Hospital, Oslo, Norway.
• Prof Ronald F van Vollenhoven, is Professor and Director of the Amsterdam Rheumatology and Immunology Center ARC; Chief of the Department of Rheumatology and Clinical Immunology at the AMC; and Head of the Department of Rheumatology at VUMC (VU University Medical Center) in Amsterdam, the Netherlands.
• Prof Ferdinand Breedveld, is Professor and Head of the Department of Internal Medicine and Rheumatology at Leiden University Medical Centre, Leiden, the Netherlands.
• Anonymous, German KOL, is a Professor of Medicine at a leading German university hospital.
• Anonymous, German KOL, is a Professor of Medicine at a leading German university hospital.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Chronic Urticaria Or Hives - Pipeline Review, H2 2019

Chronic Urticaria Or Hives - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Chronic Urticaria Or Hives - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H2 2019, provides an overview of ...

Kidney Transplant Rejection - Pipeline Review, H2 2019

Kidney Transplant Rejection - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Kidney Transplant Rejection - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Kidney Transplant Rejection - Pipeline Review, H2 2019, provides an overview ...

Diabetic Macular Edema - Pipeline Review, H1 2020

Diabetic Macular Edema - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Diabetic Macular Edema - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Macular Edema - Pipeline Review, H1 2020, provides an overview of the Diabetic ...


ref:plp2018

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on